Ken Griffin Equillium, Inc. Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$0.73 - $3.0 $146 - $600	200 New	200 $0
Q3 2023 Nov 14, 2023	SELL	$0.72 - $0.9 $720 - $900	-1,000 Reduced 83.33%	200 $0
Q2 2023 Aug 14, 2023	BUY	$0.49 - $0.79 $588 - $948	1,200 New	1,200 $0
Q4 2022 Feb 14, 2023	SELL	$0.83 - $2.26 $26,560 - $72,320	-32,000 Reduced 84.43%	5,900 $6,000
Q3 2022 Nov 14, 2022	BUY	$1.93 - $3.14 $73,147 - $119,006	37,900 New	37,900 $84,000

11.3M

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $21M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.